Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
Recruiting
This is a multi-center clinical trial in Cytomegalovirus (CMV) seronegative prospective liver transplant recipients to determine the efficacy of two doses of Cytomegalovirus-Modified Vaccinia Ankara (CMV-MVA) Triplex CMV vaccine pre-transplant. The primary objective is to assess the effect of pre-transplant (Tx) Triplex vaccination on duration of CMV antiviral therapy (AVT) within the first 100 days post-Tx in CMV seropositive donor (D+) and seronegative (R-) (D+R-) liver transplant recipients (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: University of Alabama at Birmingham, School of Medicine, Birmingham, Alabama +17 locations
Conditions: Liver Transplant
An Exercise Prehabilitation Intervention for Improving Mobility and Recovery Outcomes in Patients Undergoing Head and Neck Cancer Surgery
Recruiting
This clinical trial evaluates a prehabilitation exercise intervention for improving mobility and recovery outcomes in patients undergoing surgery for head and neck cancer. Prehabilitation focuses on optimizing health before surgery in order to improve outcomes after surgery. Prehabilitation may include aspects of nutrition, exercise, mental health, or a combination of these. Exercise has been proven to improve anxiety, depression, fatigue, health related quality of life, and physical function am... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
04/11/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Head and Neck Carcinoma
Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression
Recruiting
The goal of this clinical trial is to test the use of creatine monohydrate supplementation with resistance training to preserve muscle mass and help lessen prostate cancer progression. The main question it aims to answer is if this treatment will help maintain muscle mass to help in reducing fatigue and improving physical function, independence, and quality of life. Participants will be asked to participate in a 52-week exercise intervention consisting of a twice weekly telehealth resistance t... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Metastatic Prostate Cancer
Ketamine for Veterans With Parkinson's Disease
Recruiting
Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide. Unfortunately, there is a lack of effective treatments for depression in PD. Ketamine, which has rapid and potent antidepressant effects, is a potential option but has not been tested in Veterans with PD. Studies in rodents show that ketamine may not only improve depression i... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
04/11/2025
Locations: San Francisco VA Medical Center, San Francisco, CA, San Francisco, California
Conditions: Parkinson's Disease
Study of STP938 in Advanced Solid Tumours
Recruiting
The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy. The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Comprehensive Hematology Oncology, LLC, Saint Petersburg, Florida +6 locations
Conditions: Solid Tumor
Mobile Mental Health Stigma Reduction Intervention Among Black Adults
Recruiting
Major depressive and anxiety disorders are highly prevalent in the general population and are a leading cause of disability. Black adults have a high burden of depression and anxiety. This study aims to assess a self- administered video-based intervention to reduce mental illness stigma and medical mistrust among Black adults with moderate to severe depression or anxiety.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
04/11/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Anxiety, Depression, Health Knowledge, Attitudes, Practice, Stigmatization, Mobile Phone Use
Brain Mechanisms of Reducing Polysubstance Use
Recruiting
The proposed study will test whether neurofeedback (NF) could optimize integrative body-mind training (IBMT) practice.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: YiYuan Tang, Phoenix, Arizona
Conditions: Multiple Drug Use
A Conversational Agent (Cecebot) to Improve Insomnia in Stage I-III Breast Cancer Survivors
Recruiting
This clinical trial evaluates the effect of conversational agent, Cecebot, on improving insomnia in stage I-III breast cancer survivors. Sleep disturbance ranks among the top concerns reported by breast cancer survivors and is associated with poor quality of life. Many breast cancer survivors also have decreased physical activity, which may also have a negative impact on sleep and quality of life. Cognitive behavioral therapy for insomnia (CBTi) and physical activity interventions have individua... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Insomnia
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
Recruiting
CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of CDR404 in adult patients who have the appropriate germline human leukocyte antigen HLA-A\*02:01 tissue marker and whose cancer is positive for MAGE-A4.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: University of Miami, Miami, Florida +16 locations
Conditions: Select Advanced Solid Tumors
Speech Motor Learning and Retention (Master Protocol)
Recruiting
The overall goal of this research is to test a new model of speech motor learning, whose central hypothesis is that learning and retention are associated with plasticity not only in motor areas of the brain but in auditory and somatosensory regions as well.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
04/11/2025
Locations: Yale Child Study Center, New Haven, Connecticut
Conditions: Speech
Speech Motor Learning and Retention (Aim 1)
Recruiting
The overall goal of this research is to test a new model of speech motor learning, whose central hypothesis is that learning and retention are associated with plasticity not only in motor areas of the brain but in auditory and somatosensory regions as well. The strategy for the proposed research is to identify individual brain areas that contribute causally to retention by disrupting their activity with transcranial magnetic stimulation (TMS). Investigators will also use functional magnetic reso... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
04/11/2025
Locations: Yale Child Study Center, New Haven, Connecticut
Conditions: Speech
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Recruiting
This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. This study has two (2) major parts: Phase 1a Dose Escalation and Phase 1b Dose Expansion. The aim of the dose escalation part will be to test the safety of 27T51 in a small number of participants to fi... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +3 locations
Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer